New combo therapy aims to tame deadly immune storm with fewer side effects

NCT ID NCT06160791

First seen Jan 04, 2026 · Last updated May 07, 2026 · Updated 20 times

Summary

This study tests a new treatment for adults with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system attacks the body. The treatment combines a targeted drug (ruxolitinib) with a shorter, milder version of standard therapy to reduce side effects while still controlling the disease. About 36 newly diagnosed adults will take part to see if this approach is safe and effective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California Davis Comprehensive Cancer Center

    RECRUITING

    Sacramento, California, 95817, United States

    Contact

    Contact Email: •••••@•••••

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92697, United States

    Contact

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.